Global pharmaceutical giant Eli Lilly & Co. is seeking tax incentives for a potential 236-acre biomanufacturing plant in ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Major pharmaceutical manufacturing company Eli Lilly is considering a $5.7 billion investment into a facility in Houston.

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

With $27 billion earmarked to expand its U.S. production footprint starting this year, Eli Lilly is busy scouting out ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...

Eli Lilly has proposed investing $5.9 billion to build a pharmaceutical facility in Houston's Generation Park.

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

A major pharmaceutical manufacturing company is considering planting ground in Houston, with a $5.7 billion proposed investment into a new facility. Eli Lilly applied for a tax abatement under ...

Drug prices in the United States are astronomical and climbing. Many analysts blame mergers and acquisitions among ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.